Literature DB >> 15131157

Variable ratio of hepatitis C virus RNA to viral core antigen in patient sera.

Christian G Schüttler1, Christine Thomas, Thomas Discher, Georg Friese, Jürgen Lohmeyer, Ralph Schuster, Stephan Schaefer, Wolfram H Gerlich.   

Abstract

Quantification of hepatitis C virus (HCV) core antigen and RNA in serum samples leads to a highly variable ratio of both. It is not clear whether this is due to the inaccuracy of RNA quantification or whether both are independent parameters in a certain range. We established a real-time reverse transcription (RT)-PCR for HCV RNA that combines very high sensitivity with a large dynamic range and minimal standard deviations. The assay was calibrated with the first international standard, 96/790, and the international genotype panel for HCV from the National Institute of Biological Standardisation and Control. A linear readout was obtained between 200 and 5 x 10(7) IU/ml. The detection limit was 80 IU/ml, the reproducibility was <0.05 log, and the standard error within one run was <0.01. Comparison of the method with the Roche Monitor competitive RT-PCR revealed its high accuracy. The core protein concentration was determined within a range from 1.5 to 400 pg/ml by using the preliminary trak-C assay from Ortho Clinical Diagnostics. Correlating the HCV RNA levels with core antigen concentrations in 197 serum samples from 23 interferon-treated patients, a average ratio of 7,900 IU of HCV RNA per pg of core antigen was estimated, but the variability of this ratio exceeded largely the variability of the two assays, ranging from 50 to 20,000 IU/pg. Theoretically, HCV should contain ca. 43,000 IU of RNA/pg core. In conclusion, the core antigen assay seems to detect, in addition to complete virions, RNA-free core protein structures, which enhances its sensitivity (98% in this group). The variable ratio of RNA and core protein is not mainly due to standard deviations of quantification but could be an additional parameter for treatment follow-up and state of viral replication.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15131157      PMCID: PMC404599          DOI: 10.1128/JCM.42.5.1977-1981.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  19 in total

Review 1.  EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement.

Authors: 
Journal:  J Hepatol       Date:  1999       Impact factor: 25.083

2.  Quantitation of hepatic hepatitis C virus RNA in patients with chronic hepatitis C. Relationship with severity of disease, viral genotype and response to treatment.

Authors:  A Gervais; M Martinot; N Boyer; A Auperin; W Le Breton; C Degott; D Valla; P Marcellin
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

3.  Quantitative detection of hepatitis C virus RNA by light cycler PCR and comparison with two different PCR assays.

Authors:  M Schröter; B Zöllner; P Schäfer; R Laufs; H H Feucht
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

4.  Influence of correct secondary and tertiary RNA folding on the binding of cellular factors to the HCV IRES.

Authors:  F E Odreman-Macchioli; S G Tisminetzky; M Zotti; F E Baralle; E Buratti
Journal:  Nucleic Acids Res       Date:  2000-02-15       Impact factor: 16.971

5.  Quantitation of hepatitis C virus RNA by third generation branched DNA-based signal amplification assay.

Authors:  R S Ross; S Viazov; S Sarr; S Hoffmann; A Kramer; M Roggendorf
Journal:  J Virol Methods       Date:  2002-03       Impact factor: 2.014

6.  Quantitation of HCV RNA using real-time PCR and fluorimetry.

Authors:  F Komurian-Pradel; G Paranhos-Baccalà; M Sodoyer; P Chevallier; B Mandrand; V Lotteau; P André
Journal:  J Virol Methods       Date:  2001-06       Impact factor: 2.014

7.  Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients.

Authors:  P Maillard; K Krawczynski; J Nitkiewicz; C Bronnert; M Sidorkiewicz; P Gounon; J Dubuisson; G Faure; R Crainic; A Budkowska
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

8.  Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy.

Authors:  Hugo R Rosen; Ruy R Ribeiro; Leor Weinberger; Stephanie Wolf; Minjun Chung; David R Gretch; Alan S Perelson
Journal:  J Hepatol       Date:  2002-07       Impact factor: 25.083

9.  Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication.

Authors:  Magali Bouvier-Alias; Keyur Patel; Harel Dahari; Stéphanie Beaucourt; Patrick Larderie; Lawrence Blatt; Christophe Hezode; Gaston Picchio; Daniel Dhumeaux; Avidan U Neumann; John G McHutchison; Jean-Michel Pawlotsky
Journal:  Hepatology       Date:  2002-07       Impact factor: 17.425

10.  Comparative evaluation of the VERSANT HCV RNA 3.0, QUANTIPLEX HCV RNA 2.0, and COBAS AMPLICOR HCV MONITOR version 2.0 Assays for quantification of hepatitis C virus RNA in serum.

Authors:  Jeffrey J Germer; Paul J Heimgartner; Duane M Ilstrup; W Scott Harmsen; Greg D Jenkins; Robin Patel
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

View more
  18 in total

1.  Strong correlation between liver and serum levels of hepatitis C virus core antigen and RNA in chronically infected patients.

Authors:  V Descamps; A Op de Beeck; C Plassart; E Brochot; C François; F Helle; M Adler; N Bourgeois; D Degré; G Duverlie; S Castelain
Journal:  J Clin Microbiol       Date:  2011-12-07       Impact factor: 5.948

2.  Usefulness of the hepatitis C virus core antigen assay for screening of a population undergoing routine medical checkup.

Authors:  Catherine Gaudy; Catherine Thevenas; Jean Tichet; Nicole Mariotte; Alain Goudeau; Frédéric Dubois
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

3.  Toll-like receptor 2 senses hepatitis C virus core protein but not infectious viral particles.

Authors:  Marco Hoffmann; Mirjam B Zeisel; Nikolaus Jilg; Glaucia Paranhos-Baccalà; Françoise Stoll-Keller; Takaji Wakita; Peter Hafkemeyer; Hubert E Blum; Heidi Barth; Philipp Henneke; Thomas F Baumert
Journal:  J Innate Immun       Date:  2009-06-23       Impact factor: 7.349

4.  Is hepatitis C virus core antigen an adequate marker for community screening?

Authors:  Yuan-Hung Kuo; Kuo-Chin Chang; Jing-Houng Wang; Pei-Shan Tsai; Shu-Feng Hung; Chao-Hung Hung; Chien-Hung Chen; Sheng-Nan Lu
Journal:  J Clin Microbiol       Date:  2012-03-29       Impact factor: 5.948

5.  Comparison of serum hepatitis C virus (HCV) RNA and core antigen levels in patients coinfected with human immunodeficiency virus and HCV and treated with interferon plus ribavirin.

Authors:  A Pivert; C Payan; P Morand; S Fafi-Kremer; J Deshayes; F Carrat; S Pol; P Cacoub; C Perronne; F Lunel
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

6.  Life cycle process dependencies of positive-sense RNA viruses suggest strategies for inhibiting productive cellular infection.

Authors:  Harsh Chhajer; Vaseef A Rizvi; Rahul Roy
Journal:  J R Soc Interface       Date:  2021-11-10       Impact factor: 4.118

7.  Intracellular Hepatitis C Virus Modeling Predicts Infection Dynamics and Viral Protein Mechanisms.

Authors:  Thomas R Aunins; Katherine A Marsh; Gitanjali Subramanya; Susan L Uprichard; Alan S Perelson; Anushree Chatterjee
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

Review 8.  HCV core antigen plays an important role in the fight against HCV as an alternative to HCV-RNA detection.

Authors:  Yuhan Wang; Wang Jie; Jiang Ling; Huang Yuanshuai
Journal:  J Clin Lab Anal       Date:  2021-03-31       Impact factor: 2.352

9.  Is HCV core antigen a reliable marker of viral load? An evaluation of HCV core antigen automated immunoassay.

Authors:  Emilia Hadziyannis; Martha Minopetrou; Anastasia Georgiou; Fotini Spanou; John Koskinas
Journal:  Ann Gastroenterol       Date:  2013

10.  HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes.

Authors:  Anna Rosa Garbuglia; Alessia Monachetti; Claudio Galli; Rosella Sabatini; Monica Lucia Ferreri; Maria Rosaria Capobianchi; Patrizia Bagnarelli
Journal:  BMC Infect Dis       Date:  2014-04-23       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.